ETON Stock Analysis
ET
Uncovered
Eton Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 28 full-time employees. The company went IPO on 2018-11-09. The firm is primarily focused on hospital injectable and pediatric rare disease products. The Company’s product portfolio includes Orphan Drugs and Royalty Products. The orphan drug products include Alkindi Sprinkle (hydrocortisone granules), Carglumic Acid tablets, Dehydrated Alcohol Injection, and Zeneo Hydrocortisone Autoinjector. The firm's royalty products category includes Alaway Preservative Free (ketotifen fumarate) and Neurology Oral Liquids. The firm's neurology oral liquid products include EPRONTIA (topiramate oral solution), Zonisamide Oral Suspension, and Lamotrigine for Oral Suspension. The Company’s solutions range includes from early clinical-stage to commercial stage, including research and development (R&D) formulations, as well as clinical research services. The firm has an interest in betaine anhydrous for oral solution.